London South East Logo | UK Share Price information



Register
Login:
Share:
Email Facebook Twitter




Sareum Share Chat (SAR)



Share Price: 0.875Bid: 0.85Ask: 0.90Change: 0.00 (0.00%)No Movement on Sareum
Spread: 0.05Spread as %: 5.88%Open: 0.875High: 0.875Low: 0.875Yesterday’s Close: 0.875


Share Discussion for Sareum


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


maidit308
Posts: 589
Off Topic
Opinion:No Opinion
Price:0.875
re strange
Today 21:13
OK ajithoth we will see £ but last year we was saying on this BB that no one had any orally taken immunotherapy cancer drug in development ready for market apart from us an lilly and we know that lilly had to go back to drawing board
with theres £ and we know that [PARP] INHIBITOR don't work on its own without chk1 to keep it in check
SIERRA said that in there last presentation and that there next test was to combine PARP inhibitor with SRA737
and we will have result in Feb £ so it seems strange that astra just come up with a PARP thats oral and work
fine on its own ready for the shop£

anyway many thanks for your answer £.LOL this drug business is just too complicated for us mere mortal
we will never know what's going on

regards
 
ajithoth
Posts: 70
Off Topic
Opinion:No Opinion
Price:0.875
RE: re strange
Today 18:00
Hi Maidit, - theres no connection I think.
Lynparza is a PARP inhibitor taken in tablet form.
There's always the possibility of a PARP and CHK1 being used in conjunction with each other in the future, depending on which type of cancer is being targetted - we can only wait and see.
maidit308
Posts: 589
Off Topic
Opinion:No Opinion
Price:0.875
re strange
Today 14:52
has SIERRA sold some of its findings on chk1 SRA737and [PARP] TO ASTRA who knows??? tablet form that's a first??

regards
maidit308
Posts: 589
Off Topic
Opinion:No Opinion
Price:0.875
re strange
Today 14:45
FTSE 100 pharma giant AstraZeneca PLC (LON:AZN) has received approvals from Japanese authorities for two of its drugs.
First up is Lynparza which has been approved by the Japanese Ministry of Health, Labour and Welfare for use as a maintenance therapy in women with ovarian cancer who responded to chemotherapy.
READ: Immuno-oncology: What does 2018 have in store for Big Pharma and their cancer immunotherapies?
Lynparza is the first poly ADP-ribose polymerase (PARP) inhibitor to be approved in Japan.
Trials showed that by taking a Lynparza tablet twice a day ovarian cancer patients could live longer without their disease worsening.

could be something could be nothing

regards
JonTangle
Posts: 569
Off Topic
Opinion:No Opinion
Price:0.875
RE: Sierra tweet!!!
Today 08:51
https://www.thebalance.com/top-cancer-drugs-2663234

Just to put some meat on the bones...
boss007
Posts: 1,019
Observation
Opinion:Strong Buy
Price:0.875
RE: Sierra tweet!!!
Sat 15:32
Great points.....the more. Combo trials and the more amazing results our slice goes up so looking brilliant .....Thoth 20p-40p on this alone looks like a great shout!!!!!
Num4
Posts: 1,133
Off Topic
Opinion:No Opinion
Price:0.875
Lilly compound
Sat 11:18
https://www.chemistryworld.com/news/lilly-pushes-continuous-drug-production-limits/3007584.article

Spending more than enough to improve drug formation for their chk1 inhibitor. Confident in its development and ours is ~1250x more selective against chk2.
They are certainly ahead of the race but it looks like ours will be better.
Sierra will be more comfortable spending money to advance the trials with that tweet below.
Num4
Posts: 1,133
Off Topic
Opinion:No Opinion
Price:0.875
RE: Sierra tweet!!!
Sat 10:55
Yeah seen that this morning. Without knowing the full details of our licence we can only assume that we will only see royalties of products developed. The more "products" the better so the expansion if the trials into Parp and BRCA gives us a 100% increase in our possibility of having a product approved for treatment.
Dont think we will see a milestone for them expanding the target group, would love to be wrong though.
Broker note would help build momentum into the Feb news, with some decent risk analysis showing the potential income from chk1, then SRRA release updates reducing that risk and Sareum expand on the potential in their Feb news update.
Tim knows the market size better than anyone and would be able to give an estimate of sales income. Can't see why they woukdnt want to do that if they care about shareholder value. Surely their pockets are lined enough now...
Krone
Posts: 204
Off Topic
Opinion:No Opinion
Price:0.875
View Thread (2)
Sierra tweet!!!
Sat 09:10
SRA737 prospective patient selection strategy validated by positive clinical data reported by NCI for Chk1/2i prexasertib in Ovarian Cancer – monotherapy efficacy seen in PARP-insensitive, BRCA-wild type patients. SRRA strategic update coming in February! ow.ly/R6R630hSXde
ajithoth
Posts: 70
Off Topic
Opinion:No Opinion
Price:0.875
RE: Chk1 doing very well.
Fri 19:42
Hi JonBell, hopefully our CHK1 will have far fewer side effects if any.
In Lilly's trial of Prexasertib it looks like some of the patients had to have dose reductions due to severely low white blood cell counts. Although it does look like the patients had a better and longer outcome than those not taking it. And I think this was also last chance saloon, treated with this when all other treatments had failed or stopped working.
Ours has no CHK2 inhibition which is hopefully better than a drug with CHK1 and CHK2 inhibition.
Best in class not first in class.




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.